Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines
Open Access
- 3 January 1997
- journal article
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 126 (1) , 83-90
- https://doi.org/10.1016/s0303-7207(96)03974-3
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor SuperfamilyScience, 1995
- Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancerUrologic Oncology: Seminars and Original Investigations, 1995
- A transcriptional co-repressor that interacts with nuclear hormone receptorsNature, 1995
- Human primary prostate tumor cell line, ALVA‐31: A new model for studying the hormonal regulation of prostate tumor cell growthThe Prostate, 1993
- Newly identified actions of the vitamin D endocrine systemEndocrine Reviews, 1992
- 1,25(OH)2-vitamin D3, a steroid hormone that produces biologic effects via both genomic and nongenomic pathwaysThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- RXRβ: A coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elementsCell, 1991
- Stimulation of 1,25-dihydroxyvitamin D3 receptor gene expression in cultured cells by serum and growth factorsJournal of Bone and Mineral Research, 1991
- Jun-Fos and receptors for vitamins A and D recognize a common response element in the human osteocalcin geneCell, 1990
- Vitamin D Receptors: Nature and FunctionAnnual Review of Nutrition, 1986